Microcap Ledger Neumora Therapeutics, Inc. $NMRA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Watertown, MA
- Fiscal year end
- December 31
- Shares outstanding
- 187,895,912 [10-Q 2026-08-14]
What the company doesAI summary of filing
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for brain and centrally mediated diseases. The company's pipeline includes navacaprant, a kappa opioid receptor antagonist in Phase 3 development for major depressive disorder; NMRA-511, a vasopressin 1a receptor antagonist in Phase 1b for agitation associated with Alzheimer's disease; NMRA-898, an M4 positive allosteric modulator in Phase 1 for schizophrenia; NMRA-215, an NLRP3 inhibitor in preclinical development for obesity; NMRA-GCase, a glucocerebrosidase activator in preclinical development for Parkinson's disease; and NMRA-CK1δ, a casein kinase inhibitor in preclinical development for amyotrophic lateral sclerosis. The company is pre-revenue and generates no product sales at this stage. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$96.54M | −$85.93M | $116.83M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | $236.93M | −$206.44M | $182.53M | [DEF 14A 2026-04-17] |
| FY ended Dec 2024 | — | $243.79M | −$182.94M | $142.15M | [DEF 14A 2026-04-17] |
- Quarterly cash burn
- −$42.97M
- Cash runway Estimate
- ~8.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 161,561,064 | [10-Q 2024-11-12] |
| 2025-02-24 | 161,978,923 | [10-K 2025-03-03] |
| 2025-05-05 | 161,747,922 | [10-Q 2025-05-12] |
| 2025-08-01 | 161,945,427 | [10-Q 2025-08-06] |
| 2025-11-01 | 167,089,114 | [10-Q 2025-11-06] |
| 2026-03-23 | 182,040,945 | [10-K 2026-03-30] |
| 2026-05-01 | 185,284,244 | [10-Q 2026-05-07] |
| 2026-08-10 | 187,895,912 | [10-Q 2026-08-14] |
- Shelf registration
- S-3ASR filed 2024-10-01; declared effective 2025-03-26 [S-3ASR 2024-10-01]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-05-16. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-05-16 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-16] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-21 | Aurora Daljit Singh | exercise | 20,553 | $0.72 | [4 2026-08-21] |
| 2026-08-21 | Aurora Daljit Singh | sell | 20,553 | $1.59 | [4 2026-08-21] |
| 2026-08-21 | Aurora Daljit Singh | exercise | 21,055 | $0.72 | [4 2026-08-21] |
| 2026-08-21 | Aurora Daljit Singh | sell | 21,055 | $1.60 | [4 2026-08-21] |
| 2026-08-20 | Aurora Daljit Singh | exercise | 67,741 | $0.72 | [4 2026-08-21] |
| 2026-08-20 | Aurora Daljit Singh | sell | 67,741 | $1.51 | [4 2026-08-21] |
| 2026-08-20 | Aurora Daljit Singh | exercise | 21,685 | $0.72 | [4 2026-08-21] |
| 2026-08-20 | Aurora Daljit Singh | exercise | 45,026 | $0.72 | [4 2026-08-21] |
| 2026-08-20 | Aurora Daljit Singh | sell | 66,711 | $1.51 | [4 2026-08-21] |
| 2026-08-19 | Aurora Daljit Singh | exercise | 13,268 | $0.72 | [4 2026-08-19] |
| 2026-08-19 | Aurora Daljit Singh | exercise | 17,732 | $0.72 | [4 2026-08-19] |
| 2026-08-19 | Aurora Daljit Singh | sell | 31,000 | $1.65 | [4 2026-08-19] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 8-K | Results of operations; Director or officer change |
| 2026-07-27 | 8-K | Other events |
| 2026-06-15 | 8-K | Material agreement entered; New financial obligation; Exit or disposal costs |
| 2026-05-29 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-05-04 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-17 | DEF 14A | Proxy statement |
| 2026-04-01 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-03-30 | 10-K | Annual report |
Alerts for $NMRA
Email me when Neumora Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.